Investigating Abeta and alpha-synuclein toxicity by analyzing single-cell dynamic

描述（由申请人提供）：神经退行性疾病对社会来说是一个重大且日益增加的负担。特别是，阿尔茨海默病和帕金森病是世界上最常见的神经退行性疾病，在美国分别影响540万和50万人。事实上，据估计，2010年阿尔茨海默病和相关痴呆症的全球成本约占世界国内生产总值（GDP）的1%。尽管我们知道几乎所有的神经退行性疾病都起源于细胞中特定蛋白质的折叠和运输问题，但根本没有有效的治疗方法来阻止或治愈这些疾病。这至少部分是由于在细胞水平上缺乏对疾病病理机制的理解。本研究以出芽酵母（Saccharomyces cerevisiae）为细胞模型系统。该系统先前已被证明概括了在人类神经退行性疾病中观察到的神经元毒性的独特特征。值得注意的是，之前所有酵母和神经元模型的分析都局限于稳态体积测量，这是许多细胞的平均值，基本上掩盖了所有细胞内动力学。这些测量不能揭示重要的动态特性，这需要随时间观察单个细胞。相比之下，本文提出了一种系统测量单细胞对疾病相关蛋白表达的全局反应的新方法，如？-突触核蛋白（帕金森病）和A？多肽（阿尔茨海默病）通过遵循生物化学途径、蛋白质定位和运输、细胞器和代谢物在单个细胞中的时间依赖性变化。生物回路在细胞内起作用，因此需要单细胞分析来揭示它们的所有行为。单细胞分辨率将通过开发创新的微流控分析平台来实现，该平台允许随时间对单个细胞进行成像，并允许对单个细胞的动态响应进行量化。这种系统的单细胞测量将揭示与细胞毒性相关的新机制，并将有助于系统级理解a ？然后呢?-突触核蛋白毒性细胞生理学。此外，这种高通量成像平台将用于研究约100种小分子化合物的细胞生物学效应，这些化合物之前通过大规模小分子筛选被确定为潜在的候选药物，目前正在验证它们在神经元中的功效。用本文描述的高通量成像平台所做的发现将在哺乳动物神经系统中得到验证。值得注意的是，本文所描述的系统级单细胞分析方法以前从未应用于神经退行性疾病的研究，并且有可能揭示全球范围内细胞内扰动的新见解，这对于确定对抗这些疾病的有效治疗方法是必要的。

DESCRIPTION (provided by applicant): Neurodegenerative diseases represent a significant and increasing burden on society. In particular, Alzheimer's disease and Parkinson's disease are the most common neurodegenerative disorders in the world and affect 5.4 million and >500,000 people in the USA, respectively. In fact, the global cost of Alzheimer's disease and related dementias was estimated in 2010 to be ~1% of the world's gross domestic product (GDP). Despite the knowledge that virtually all neurodegenerative diseases originate with problems in the folding and trafficking of specific proteins in cells, there are simply no effectiv treatments to halt or cure these diseases. This is at least in part due to the lack of a mechanisti understanding of the disease pathology at the cellular level. The research proposed herein uses the budding yeast, Saccharomyces cerevisiae, as a cellular model system. This system has previously been shown to recapitulate unique features of neuronal toxicity observed in human neurodegenerative diseases. Significantly, all previous analyses in both yeast and neuronal models were limited to steady-state bulk measurements, which average over many cells and mask essentially all intracellular dynamics. These measurements cannot reveal important dynamic properties, which require observation of single cells over time. By contrast, proposed herein is a novel approach to systematically measure the global response of single cells to the expression of disease-relevant proteins, such as ?-synuclein (Parkinson's disease) and the A? peptide (Alzheimer's disease) by following the time-dependent changes of biochemical pathways, protein localization and trafficking, organelles, and metabolites in single cells. Biological circuits function inside cells and hence require a single-cell analysis to uncover all their behaviors. The single-cell resolution will be achieved through the development of an innovative microfluidic analysis platform, which permits the imaging of individual cells over time and allows for the quantification of dynamic responses in single cells. Such systematic single-cell measurements will reveal novel mechanisms relevant to cellular toxicity and will contribute to a systems-level understanding of how A? and ?-synuclein poison cellular physiology. Further, this high-throughput imaging platform will be employed to investigate the cell biological effects of ~100 small- molecule compounds that were previously identified through large-scale small-molecule screening as potential drug candidates and are currently being verified for their efficacy in neurons. Discoveries made with the high- throughput imaging platform described herein will later be validated in mammalian neuronal systems. Significantly, the systems-level, single-cell analysis approach described herein has never before been applied to the investigation of neurodegenerative diseases and has the potential to uncover novel insights about intracellular perturbations on a global scale, which is necessary for identifying effective therapeutics to combat these diseases.